Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1701 - 1725 of 2373 in total
GW870086X has been investigated for the treatment of ASTHMA.
Investigational
Investigational
BI-836880 is a humanized bispecific nanobody that targets VEGF and Ang2.
Investigational
Investigational
RGLS-8429 is an investigational anti-miR-17 oligonucleotide.
Investigational
Icariin has been investigated for the basic science of the Pharmacokinetic Profile of Icariin in Humans.
Investigational
Matched Iupac: … 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl …
NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).
Investigational
H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine . It offers the benefit of preferentially killing spliceosome-mutant cancer cells whereas other splicesome inhibitors, such as the pladienolide analogue E7107, show no such preferential targeting . H3B-8800 was granted orphan drug status by the FDA in August 2017 and...
Investigational
Experimental
Matched Iupac: … sodium 8-hydroxy-7-iodoquinoline-5-sulfonic acid hydrogen carbonate …
Urolithin A is a metabolite of ellagic acid. It has been demonstrated to stimulate mitophagy and improve muscle health in old animals and in preclinical models of aging.
Investigational
Experimental
Matched Mixtures name: … CitraNatal 90 DHA …
Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation...
Investigational
Matched Mixtures name: … TADA PLUS 30/20 MG FILM KAPLI TABLET ,8 ADET …
Alvespimycin is a derivative of geldanamycin and heat shock protein (HSP) 90 inhibitor. It has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent. In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable properties such as reduced metabolic...
Investigational
Matched Description: … Alvespimycin is a derivative of geldanamycin and heat shock protein (HSP) 90 inhibitor. …
Cefroxadine is an orally available cephalosporin antibiotic. As part of its drug class, it shares structural properties to cefalexin as well as its activity spectrum. It was used in Italy but has since been withdrawn.
Withdrawn
Matched Iupac: … (6R,7R)-7-[(2R)-2-amino-2-(cyclohexa-1,4-dien-1-yl)acetamido]-3-methoxy-8-oxo-5-thia-1-azabicyclo[4.2.0 …
BMS-817399 is under investigation in clinical trial NCT01404585 (Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis).
Investigational
BMS-813160 is under investigation in clinical trial NCT03496662 (BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)).
Investigational
Investigational
ATX-F8-117 is an investigational peptide derived from Factor VIII. Developed by Apitope, it is being investigated for the treatment of hemophilia A.
Investigational
RWJ-800088 is a synthetic PEGylated thrombopoietin (TPO) mimetic (TPOm) peptide with no sequence homology to endogenous TPO.
Investigational
Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
Experimental
Fibrodysplasia ossificans progressiva (FOP) is a rare autosomal dominant disorder of episodic, progressive heterotropic ossification. FOP is characterized by episodic inflammatory episodes, which may be precipitated by trauma, including immunizations and minor tissue damage, which usually result in ossification of the lesion. Patients experience abnormal cartilage formation, growth plate dysplasia,...
Investigational
REP8839 is a novel methionyl-tRNA synthetase (MetS) inhibitor being developed by Replidyne (GlaxoSmithKline licensed REP8839 to Replidyne in June of 2003).
Investigational
Displaying drugs 1701 - 1725 of 2373 in total